Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark Bloch

Showing results (71-80 of 83) with videos related to

Pageof 9
Sort By:
Open Forum Infectious Diseases|November 25, 2024
4CMenB Breadth of Immune Response, Immunogenicity, and Safety: Results From a Phase 3 Randomized, Controlled, Observer Blind Study in Adolescents and Young AdultsTerry Nolan, Chiranjiwi Bhusal, Jiří Beran, et al.
The Lancet. HIV|September 19, 2017
Raltegravir 1200 mg once daily versus raltegravir 400 mg twice daily, with tenofovir disoproxil fumarate and emtricitabine, for previously untreated HIV-1 infection: a randomised, double-blind, parallel-group, phase 3, non-inferiority trialPedro Cahn, Richard Kaplan, Paul E Sax, et al.
Cell Reports. Medicine|December 3, 2024
Age-related clonal hematopoiesis and HIV infection are associated with geriatric outcomes: The ARCHIVE studyWin Min Han, Hossain M S Sazzad, Mark Bloch, et al.
The Lancet. Infectious Diseases|December 8, 2024
Breadth of immune response, immunogenicity, reactogenicity, and safety for a pentavalent meningococcal ABCWY vaccine in healthy adolescents and young adults: results from a phase 3, randomised, controlled observer-blinded trialTerry Nolan, Chiranjiwi Bhusal, Jiří Beran, et al.
Lancet (London, England)|February 28, 2026
Switch to single-tablet bictegravir-lenacapavir from a complex HIV regimen (ARTISTRY-1): a randomised, open-label, phase 3 clinical trialChloe Orkin, Peter J Ruane, Malcolm Hedgcock, et al.
The Lancet. HIV|July 21, 2018
Viral suppression and HIV transmission in serodiscordant male couples: an international, prospective, observational, cohort studyBenjamin R Bavinton, Angie N Pinto, Nittaya Phanuphak, et al.
The Lancet. Infectious Diseases|March 9, 2024
Immunogenicity and safety of a bivalent (omicron BA.5 plus ancestral) SARS-CoV-2 recombinant spike protein vaccine as a heterologous booster dose: interim analysis of a phase 3, non-inferiority, randomised, clinical trialChijioke Bennett, Wayne Woo, Mark Bloch, et al.
The Journal of Infectious Diseases|July 25, 2024
Immunogenicity and Safety of Heterologous Omicron BA.1 and Bivalent SARS-CoV-2 Recombinant Spike Protein Booster Vaccines: A Phase 3 Randomized Clinical TrialChijioke Bennett, E Joy Rivers, Wayne Woo, et al.
Human Vaccines & Immunotherapeutics|October 18, 2024
Safety and immunogenicity of a modified mRNA-lipid nanoparticle vaccine candidate against COVID-19: Results from a phase 1, dose-escalation studyBrandon J Essink, Craig Shapiro, Marie Grace Dawn Isidro, et al.
Nature Medicine|February 17, 2009
Phase 2 gene therapy trial of an anti-HIV ribozyme in autologous CD34+ cellsRonald T Mitsuyasu, Thomas C Merigan, Andrew Carr, et al.
Pageof 9

Showing results (71-80 of 83) with videos related to

Sort By:
Pageof 9
Open Forum Infectious Diseases|November 25, 2024
4CMenB Breadth of Immune Response, Immunogenicity, and Safety: Results From a Phase 3 Randomized, Controlled, Observer Blind Study in Adolescents and Young AdultsTerry Nolan, Chiranjiwi Bhusal, Jiří Beran, et al.
The Lancet. HIV|September 19, 2017
Raltegravir 1200 mg once daily versus raltegravir 400 mg twice daily, with tenofovir disoproxil fumarate and emtricitabine, for previously untreated HIV-1 infection: a randomised, double-blind, parallel-group, phase 3, non-inferiority trialPedro Cahn, Richard Kaplan, Paul E Sax, et al.
Cell Reports. Medicine|December 3, 2024
Age-related clonal hematopoiesis and HIV infection are associated with geriatric outcomes: The ARCHIVE studyWin Min Han, Hossain M S Sazzad, Mark Bloch, et al.
The Lancet. Infectious Diseases|December 8, 2024
Breadth of immune response, immunogenicity, reactogenicity, and safety for a pentavalent meningococcal ABCWY vaccine in healthy adolescents and young adults: results from a phase 3, randomised, controlled observer-blinded trialTerry Nolan, Chiranjiwi Bhusal, Jiří Beran, et al.
Lancet (London, England)|February 28, 2026
Switch to single-tablet bictegravir-lenacapavir from a complex HIV regimen (ARTISTRY-1): a randomised, open-label, phase 3 clinical trialChloe Orkin, Peter J Ruane, Malcolm Hedgcock, et al.
The Lancet. HIV|July 21, 2018
Viral suppression and HIV transmission in serodiscordant male couples: an international, prospective, observational, cohort studyBenjamin R Bavinton, Angie N Pinto, Nittaya Phanuphak, et al.
The Lancet. Infectious Diseases|March 9, 2024
Immunogenicity and safety of a bivalent (omicron BA.5 plus ancestral) SARS-CoV-2 recombinant spike protein vaccine as a heterologous booster dose: interim analysis of a phase 3, non-inferiority, randomised, clinical trialChijioke Bennett, Wayne Woo, Mark Bloch, et al.
The Journal of Infectious Diseases|July 25, 2024
Immunogenicity and Safety of Heterologous Omicron BA.1 and Bivalent SARS-CoV-2 Recombinant Spike Protein Booster Vaccines: A Phase 3 Randomized Clinical TrialChijioke Bennett, E Joy Rivers, Wayne Woo, et al.
Human Vaccines & Immunotherapeutics|October 18, 2024
Safety and immunogenicity of a modified mRNA-lipid nanoparticle vaccine candidate against COVID-19: Results from a phase 1, dose-escalation studyBrandon J Essink, Craig Shapiro, Marie Grace Dawn Isidro, et al.
Nature Medicine|February 17, 2009
Phase 2 gene therapy trial of an anti-HIV ribozyme in autologous CD34+ cellsRonald T Mitsuyasu, Thomas C Merigan, Andrew Carr, et al.
Pageof 9